INTELLIGENCE: A NEW IDEA ON FLEXION THERAPEUTICS, RUMORS OF A BUYOUT $FLXN $SNY
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage. FLXN is a biopharma. There are reports of a potential buyout buy SNY. The stock is jumping as we are writing. This is suitable only for super aggressive investors as the risk of loss